奈达铂联合放疗治疗中晚期食管癌的临床观察  

Clinical observation of Nedaplatin combined with radiotherapy in the treatment of advanced esophageal carcinoma

作　　者：栾天燕[1] 李同乐[1] 尹宝玉[1] 

机构地区：[1]河北省保定市肿瘤医院,河北保定071000

出　　处：《中国医药导报》2012年第28期157-158,共2页China Medical Herald

摘　　要：目的探讨奈达铂与顺铂联合放疗治疗中晚期食管癌的近期疗效及不良反应。方法选取64例经病理学或细胞学确诊的无法手术的初治中晚期食管癌患者,随机分组,32例入奈达铂联合放疗组(治疗组),32例入顺铂联合放疗组(对照组)。同时评价疗效及不良反应。结果治疗组有效率(RR)为69%,对照组为53%,两者比较,差异有统计学意义(P<0.05)。主要不良反应为骨髓抑制、放射性食管炎,发生率治疗组与对照组差异无统计学意义(P>0.05),恶心呕吐及肾毒性发生率治疗组低于对照组(P<0.05)。结论奈达铂联合放疗治疗中晚期食管癌取得较高的临床疗效,且不良反应可耐受。Objective To investigate the efficacy and toxicity of Nedaplatin and Cisplatin combined with radiotherapy for patients with advanced esophageal cancer. Methods 64 patients with untreated advanced esophageal cancer were enrolled in this study and all of these patients were confirmed with pathology or cytology and all of them were found no chance to receive surgery treatment. These patients were randomly divided into two groups, 32 patients in treatment group were received Nedaplatin combined with radiotherapy and 32 patients, in control group were received Cisplatin combined with radiotherapy. Results The effective rate in treatment group was 69% and that in contral group was 53%, the difference was statistically significant （P 〈 0.05）. Bone marrow suppression and radiation-induced esophagitis were the major adverse reactions, the differences of the incidences between the two groups were not statistically significant （P 〉 0.05）, but the differences of the incidences of emesis and renal impairment in the two groups were statistically significant （P 〈 0.05）. Conclusion Nedaplatin combined with radiotherapy is effective in treatment of advanced esophageal cancer and the toxicity can be well tolerated.

关 键 词：奈达铂 放射治疗 食管癌 

分 类 号：R735.1[医药卫生—肿瘤]